| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Taiwan | 40 | 2021 | 2556 | 2.83 | Why? |
| Bacteremia | 5 | 2019 | 1372 | 1.52 | Why? |
| Emphysema | 2 | 2017 | 52 | 1.34 | Why? |
| Escherichia coli Proteins | 2 | 2018 | 168 | 1.29 | Why? |
| Patient Care Bundles | 2 | 2017 | 137 | 1.18 | Why? |
| Catheter-Related Infections | 2 | 2017 | 381 | 1.02 | Why? |
| Escherichia coli | 3 | 2018 | 1547 | 0.90 | Why? |
| Coinfection | 4 | 2021 | 6820 | 0.84 | Why? |
| Bacterial Infections | 5 | 2021 | 2229 | 0.80 | Why? |
| Intraabdominal Infections | 1 | 2020 | 90 | 0.78 | Why? |
| Sofosbuvir | 2 | 2021 | 518 | 0.77 | Why? |
| Mycoses | 2 | 2021 | 589 | 0.76 | Why? |
| Anti-Infective Agents | 2 | 2021 | 1766 | 0.74 | Why? |
| Pulmonary Disease, Chronic Obstructive | 5 | 2019 | 3832 | 0.74 | Why? |
| Salmonella | 1 | 2018 | 58 | 0.73 | Why? |
| Sexually Transmitted Diseases | 3 | 2021 | 694 | 0.72 | Why? |
| Thigh | 1 | 2017 | 55 | 0.72 | Why? |
| Diphtheria-Tetanus-acellular Pertussis Vaccines | 1 | 2019 | 91 | 0.71 | Why? |
| Burns, Chemical | 1 | 2017 | 16 | 0.70 | Why? |
| Anti-Bacterial Agents | 11 | 2021 | 10083 | 0.70 | Why? |
| Liver Abscess | 1 | 2017 | 42 | 0.70 | Why? |
| Klebsiella pneumoniae | 3 | 2018 | 658 | 0.70 | Why? |
| Pneumatosis Cystoides Intestinalis | 1 | 2018 | 41 | 0.70 | Why? |
| Knee Injuries | 1 | 2017 | 25 | 0.69 | Why? |
| Information Technology | 1 | 2020 | 278 | 0.69 | Why? |
| Tetanus | 1 | 2017 | 61 | 0.66 | Why? |
| Early Ambulation | 1 | 2017 | 102 | 0.65 | Why? |
| Drug Resistance, Microbial | 1 | 2021 | 419 | 0.64 | Why? |
| Syphilis | 1 | 2020 | 318 | 0.62 | Why? |
| Chemoembolization, Therapeutic | 1 | 2017 | 144 | 0.62 | Why? |
| Sepsis | 5 | 2019 | 3517 | 0.61 | Why? |
| Methemoglobinemia | 1 | 2016 | 51 | 0.61 | Why? |
| Communicable Diseases | 2 | 2021 | 2148 | 0.60 | Why? |
| Janus Kinase Inhibitors | 1 | 2021 | 682 | 0.60 | Why? |
| Pulmonary Aspergillosis | 1 | 2020 | 408 | 0.59 | Why? |
| Oral Hygiene | 1 | 2017 | 137 | 0.58 | Why? |
| Chlorhexidine | 1 | 2017 | 176 | 0.58 | Why? |
| Staphylococcal Infections | 2 | 2017 | 1099 | 0.57 | Why? |
| Methicillin-Resistant Staphylococcus aureus | 3 | 2018 | 711 | 0.57 | Why? |
| Teicoplanin | 1 | 2017 | 191 | 0.57 | Why? |
| Glycopeptides | 1 | 2017 | 199 | 0.56 | Why? |
| Oxazines | 1 | 2016 | 279 | 0.56 | Why? |
| Cephalosporins | 1 | 2017 | 250 | 0.56 | Why? |
| Carbapenems | 2 | 2017 | 343 | 0.55 | Why? |
| Enterobacteriaceae Infections | 2 | 2018 | 529 | 0.54 | Why? |
| Vancomycin | 1 | 2017 | 328 | 0.52 | Why? |
| Parenteral Nutrition | 1 | 2015 | 184 | 0.52 | Why? |
| Listeriosis | 1 | 2013 | 36 | 0.52 | Why? |
| Staphylococcus aureus | 2 | 2017 | 844 | 0.51 | Why? |
| Rehabilitation | 1 | 2019 | 386 | 0.51 | Why? |
| Government Regulation | 1 | 2020 | 842 | 0.51 | Why? |
| Escherichia coli Infections | 1 | 2017 | 348 | 0.50 | Why? |
| Invasive Pulmonary Aspergillosis | 1 | 2020 | 634 | 0.50 | Why? |
| Listeria monocytogenes | 1 | 2013 | 68 | 0.50 | Why? |
| Insurance, Health | 2 | 2019 | 634 | 0.49 | Why? |
| Airway Extubation | 4 | 2019 | 403 | 0.49 | Why? |
| Catheterization, Central Venous | 1 | 2017 | 458 | 0.48 | Why? |
| Angiotensin II Type 1 Receptor Blockers | 1 | 2018 | 520 | 0.48 | Why? |
| Abdominal Pain | 1 | 2018 | 858 | 0.48 | Why? |
| Colon | 1 | 2017 | 669 | 0.47 | Why? |
| Hydrogen Peroxide | 1 | 2017 | 680 | 0.47 | Why? |
| Microbial Sensitivity Tests | 9 | 2018 | 2886 | 0.47 | Why? |
| Pneumonia, Ventilator-Associated | 2 | 2017 | 861 | 0.47 | Why? |
| Humans | 100 | 2021 | 930598 | 0.47 | Why? |
| Mouthwashes | 1 | 2017 | 432 | 0.47 | Why? |
| Nursing Homes | 2 | 2020 | 4155 | 0.47 | Why? |
| Treatment Outcome | 18 | 2021 | 51732 | 0.46 | Why? |
| Urinary Tract Infections | 1 | 2017 | 534 | 0.44 | Why? |
| beta-Lactamases | 2 | 2017 | 759 | 0.44 | Why? |
| Embolism, Air | 1 | 2011 | 23 | 0.44 | Why? |
| Antifungal Agents | 4 | 2020 | 1828 | 0.44 | Why? |
| Gastrointestinal Tract | 1 | 2019 | 1113 | 0.42 | Why? |
| Staphylococcus | 1 | 2011 | 77 | 0.42 | Why? |
| Abdominal Injuries | 1 | 2011 | 72 | 0.41 | Why? |
| Angiotensin-Converting Enzyme Inhibitors | 2 | 2019 | 5277 | 0.41 | Why? |
| Anti-Infective Agents, Local | 1 | 2017 | 520 | 0.41 | Why? |
| Blood | 1 | 2011 | 274 | 0.40 | Why? |
| Intensive Care Units | 14 | 2020 | 29594 | 0.40 | Why? |
| Ischemia | 1 | 2017 | 901 | 0.39 | Why? |
| Valine | 2 | 2021 | 359 | 0.38 | Why? |
| Quality Improvement | 2 | 2018 | 2435 | 0.37 | Why? |
| Network Meta-Analysis | 2 | 2021 | 426 | 0.37 | Why? |
| Patient Readmission | 1 | 2018 | 1543 | 0.37 | Why? |
| Civil Defense | 1 | 2020 | 1687 | 0.37 | Why? |
| Swine Diseases | 1 | 2018 | 1219 | 0.36 | Why? |
| Bacteriological Techniques | 1 | 2011 | 239 | 0.36 | Why? |
| Wounds, Nonpenetrating | 1 | 2011 | 157 | 0.36 | Why? |
| Prisons | 1 | 2017 | 980 | 0.35 | Why? |
| Hand Hygiene | 1 | 2018 | 1493 | 0.35 | Why? |
| Guideline Adherence | 2 | 2018 | 2309 | 0.35 | Why? |
| Thrombocytopenia | 1 | 2021 | 2093 | 0.35 | Why? |
| Fungemia | 1 | 2008 | 86 | 0.34 | Why? |
| Carbamates | 2 | 2021 | 485 | 0.34 | Why? |
| Carcinoma, Hepatocellular | 1 | 2017 | 1222 | 0.33 | Why? |
| Incidence | 11 | 2021 | 25622 | 0.33 | Why? |
| Encephalitis, Japanese | 1 | 2007 | 58 | 0.33 | Why? |
| Pyrrolidines | 2 | 2021 | 558 | 0.33 | Why? |
| Candida | 3 | 2019 | 425 | 0.33 | Why? |
| Influenza, Human | 5 | 2021 | 10779 | 0.32 | Why? |
| Tuberculosis | 2 | 2020 | 2895 | 0.32 | Why? |
| Rhizopus | 1 | 2006 | 32 | 0.32 | Why? |
| Survivors | 1 | 2019 | 2619 | 0.32 | Why? |
| Long-Term Care | 4 | 2020 | 2047 | 0.31 | Why? |
| Patient Safety | 1 | 2021 | 4885 | 0.31 | Why? |
| Empyema, Pleural | 1 | 2006 | 46 | 0.30 | Why? |
| Rhabdomyolysis | 1 | 2010 | 287 | 0.30 | Why? |
| Liver Cirrhosis | 1 | 2017 | 1810 | 0.30 | Why? |
| Proportional Hazards Models | 7 | 2019 | 6543 | 0.30 | Why? |
| Imidazoles | 2 | 2021 | 631 | 0.29 | Why? |
| Liver Neoplasms | 1 | 2017 | 1666 | 0.29 | Why? |
| Dementia | 2 | 2017 | 1861 | 0.27 | Why? |
| Randomized Controlled Trials as Topic | 6 | 2021 | 10649 | 0.27 | Why? |
| Adrenergic beta-Antagonists | 2 | 2017 | 465 | 0.26 | Why? |
| Emergency Service, Hospital | 6 | 2021 | 14232 | 0.26 | Why? |
| Aged | 31 | 2020 | 215776 | 0.26 | Why? |
| Pneumonia | 3 | 2018 | 5652 | 0.26 | Why? |
| Coronavirus Infections | 10 | 2020 | 253789 | 0.25 | Why? |
| Male | 45 | 2021 | 367725 | 0.25 | Why? |
| Adenosine Monophosphate | 4 | 2021 | 5652 | 0.25 | Why? |
| Alanine | 4 | 2021 | 5687 | 0.25 | Why? |
| Respiratory Insufficiency | 4 | 2019 | 7301 | 0.25 | Why? |
| Molecular Typing | 3 | 2018 | 280 | 0.24 | Why? |
| Aspergillus | 2 | 2020 | 347 | 0.24 | Why? |
| Drug Resistance, Multiple, Bacterial | 4 | 2018 | 1115 | 0.24 | Why? |
| Environmental Microbiology | 2 | 2018 | 575 | 0.24 | Why? |
| Myocardial Infarction | 1 | 2018 | 3361 | 0.24 | Why? |
| Pneumococcal Infections | 2 | 2020 | 562 | 0.24 | Why? |
| Patient Discharge | 1 | 2018 | 5696 | 0.24 | Why? |
| Angiotensin Receptor Antagonists | 1 | 2019 | 3892 | 0.24 | Why? |
| Kidney Failure, Chronic | 1 | 2018 | 3222 | 0.23 | Why? |
| Drug Resistance, Multiple, Fungal | 2 | 2019 | 45 | 0.23 | Why? |
| Pneumonia, Viral | 9 | 2020 | 243684 | 0.23 | Why? |
| Dibenzothiepins | 1 | 2021 | 39 | 0.23 | Why? |
| Infection Control | 4 | 2020 | 23131 | 0.23 | Why? |
| APACHE | 3 | 2019 | 682 | 0.23 | Why? |
| Radiography | 3 | 2017 | 1576 | 0.22 | Why? |
| Echinocandins | 2 | 2019 | 139 | 0.22 | Why? |
| Coronavirus | 2 | 2020 | 18339 | 0.22 | Why? |
| Prognosis | 4 | 2018 | 32490 | 0.21 | Why? |
| Social Control Policies | 1 | 2020 | 54 | 0.21 | Why? |
| Asymptomatic Infections | 1 | 2020 | 7218 | 0.21 | Why? |
| Middle Aged | 35 | 2020 | 270681 | 0.21 | Why? |
| Contact Tracing | 1 | 2020 | 8448 | 0.21 | Why? |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2006 | 526 | 0.21 | Why? |
| Cobicistat | 1 | 2021 | 172 | 0.21 | Why? |
| Arthus Reaction | 1 | 2019 | 1 | 0.20 | Why? |
| Retrospective Studies | 17 | 2021 | 105322 | 0.20 | Why? |
| Cross Infection | 5 | 2018 | 8675 | 0.20 | Why? |
| Acinetobacter baumannii | 3 | 2018 | 378 | 0.20 | Why? |
| Cyproheptadine | 1 | 2019 | 8 | 0.20 | Why? |
| Pyrazines | 2 | 2021 | 1783 | 0.20 | Why? |
| Tetracyclines | 1 | 2020 | 82 | 0.20 | Why? |
| Amides | 2 | 2021 | 1864 | 0.20 | Why? |
| Compliance | 1 | 2018 | 28 | 0.19 | Why? |
| Morpholines | 1 | 2021 | 351 | 0.19 | Why? |
| Respiration, Artificial | 5 | 2020 | 22116 | 0.19 | Why? |
| Triazines | 1 | 2021 | 246 | 0.19 | Why? |
| Electrophoresis, Gel, Pulsed-Field | 1 | 2018 | 78 | 0.19 | Why? |
| Rome | 1 | 2020 | 497 | 0.19 | Why? |
| Thrombosis | 1 | 2021 | 7504 | 0.19 | Why? |
| Tetracycline Resistance | 1 | 2017 | 8 | 0.19 | Why? |
| Histamine H1 Antagonists | 1 | 2019 | 79 | 0.19 | Why? |
| Pandemics | 16 | 2021 | 389249 | 0.18 | Why? |
| Dermatomycoses | 1 | 2019 | 55 | 0.18 | Why? |
| Cefoperazone | 1 | 2017 | 6 | 0.18 | Why? |
| Databases, Factual | 6 | 2018 | 6248 | 0.18 | Why? |
| Immunocompromised Host | 3 | 2021 | 5150 | 0.18 | Why? |
| Watchful Waiting | 1 | 2020 | 276 | 0.18 | Why? |
| Fluticasone-Salmeterol Drug Combination | 1 | 2017 | 10 | 0.18 | Why? |
| Budesonide, Formoterol Fumarate Drug Combination | 1 | 2017 | 7 | 0.18 | Why? |
| Sulbactam | 1 | 2017 | 37 | 0.18 | Why? |
| Adrenal Cortex Hormones | 3 | 2021 | 6537 | 0.18 | Why? |
| Administrative Claims, Healthcare | 1 | 2018 | 124 | 0.18 | Why? |
| Pseudomonas aeruginosa | 3 | 2018 | 652 | 0.18 | Why? |
| Clostridium tetani | 1 | 2017 | 9 | 0.18 | Why? |
| Female | 33 | 2021 | 380317 | 0.18 | Why? |
| Aged, 80 and over | 17 | 2019 | 88759 | 0.18 | Why? |
| Bone Cements | 1 | 2017 | 21 | 0.18 | Why? |
| Methicillin | 1 | 2017 | 73 | 0.18 | Why? |
| Iran | 2 | 2021 | 5467 | 0.18 | Why? |
| RNA, Ribosomal, 16S | 3 | 2017 | 793 | 0.17 | Why? |
| Stroke | 2 | 2018 | 8839 | 0.17 | Why? |
| Analgesics, Non-Narcotic | 1 | 2019 | 164 | 0.17 | Why? |
| Candidiasis, Invasive | 1 | 2019 | 107 | 0.17 | Why? |
| Rupture | 1 | 2017 | 40 | 0.17 | Why? |
| Cystitis | 1 | 2017 | 45 | 0.17 | Why? |
| Darunavir | 1 | 2021 | 477 | 0.17 | Why? |
| Propensity Score | 4 | 2019 | 2690 | 0.17 | Why? |
| Penicillin Resistance | 1 | 2016 | 15 | 0.17 | Why? |
| Amphotericin B | 1 | 2019 | 256 | 0.17 | Why? |
| Catheters | 1 | 2017 | 93 | 0.17 | Why? |
| Pneumoperitoneum | 1 | 2018 | 70 | 0.17 | Why? |
| Fungi | 1 | 2021 | 471 | 0.17 | Why? |
| Disease Transmission, Infectious | 1 | 2020 | 9044 | 0.17 | Why? |
| Ventilator Weaning | 2 | 2019 | 536 | 0.17 | Why? |
| Geography, Medical | 1 | 2020 | 537 | 0.17 | Why? |
| Clinical Trials, Phase III as Topic | 1 | 2021 | 782 | 0.17 | Why? |
| Health Policy | 1 | 2017 | 6242 | 0.16 | Why? |
| Gonorrhea | 1 | 2021 | 315 | 0.16 | Why? |
| Japan | 2 | 2020 | 6653 | 0.16 | Why? |
| Drug Therapy, Combination | 2 | 2021 | 7268 | 0.16 | Why? |
| Fosfomycin | 1 | 2016 | 48 | 0.16 | Why? |
| Ciprofloxacin | 1 | 2017 | 130 | 0.16 | Why? |
| In Vitro Techniques | 1 | 2020 | 1027 | 0.16 | Why? |
| Tongue Neoplasms | 1 | 2016 | 54 | 0.16 | Why? |
| Tertiary Care Centers | 2 | 2017 | 8248 | 0.16 | Why? |
| Risk Factors | 12 | 2020 | 71621 | 0.16 | Why? |
| Time Factors | 8 | 2018 | 31397 | 0.16 | Why? |
| Fasciitis, Necrotizing | 1 | 2016 | 56 | 0.16 | Why? |
| Mucormycosis | 1 | 2006 | 832 | 0.16 | Why? |
| Nitriles | 1 | 2021 | 1053 | 0.16 | Why? |
| Survival Analysis | 3 | 2020 | 7592 | 0.16 | Why? |
| Pulmonary Embolism | 2 | 2017 | 4775 | 0.15 | Why? |
| Acetaminophen | 1 | 2019 | 326 | 0.15 | Why? |
| Gastroesophageal Reflux | 1 | 2017 | 124 | 0.15 | Why? |
| Antiviral Agents | 4 | 2021 | 41703 | 0.15 | Why? |
| Cyanosis | 1 | 2016 | 100 | 0.15 | Why? |
| Adrenergic beta-2 Receptor Agonists | 1 | 2017 | 142 | 0.15 | Why? |
| Reference Values | 1 | 2018 | 795 | 0.15 | Why? |
| Purines | 1 | 2021 | 816 | 0.15 | Why? |
| Drug Utilization | 1 | 2021 | 619 | 0.15 | Why? |
| Pyridones | 1 | 2021 | 738 | 0.15 | Why? |
| Influenza A Virus, H1N1 Subtype | 1 | 2010 | 2984 | 0.14 | Why? |
| Azetidines | 1 | 2021 | 722 | 0.14 | Why? |
| Piperidines | 1 | 2021 | 795 | 0.14 | Why? |
| Hospitals | 4 | 2019 | 11793 | 0.14 | Why? |
| False Positive Reactions | 1 | 2020 | 1338 | 0.14 | Why? |
| Antibodies, Monoclonal, Humanized | 3 | 2021 | 9335 | 0.14 | Why? |
| Ceftriaxone | 1 | 2016 | 365 | 0.14 | Why? |
| HIV Infections | 1 | 2020 | 11620 | 0.14 | Why? |
| Candidiasis | 1 | 2019 | 334 | 0.14 | Why? |
| Comorbidity | 7 | 2020 | 34796 | 0.14 | Why? |
| Methylene Blue | 1 | 2016 | 175 | 0.14 | Why? |
| Cohort Studies | 7 | 2019 | 36005 | 0.14 | Why? |
| Sex Distribution | 2 | 2018 | 2083 | 0.13 | Why? |
| Adult | 18 | 2020 | 244371 | 0.13 | Why? |
| Calcium Channel Blockers | 1 | 2017 | 367 | 0.13 | Why? |
| Delivery of Health Care | 1 | 2020 | 15909 | 0.13 | Why? |
| Cannula | 1 | 2019 | 750 | 0.13 | Why? |
| Betacoronavirus | 9 | 2020 | 204454 | 0.13 | Why? |
| Prevalence | 4 | 2020 | 25773 | 0.13 | Why? |
| Drug Synergism | 1 | 2017 | 833 | 0.13 | Why? |
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2017 | 449 | 0.13 | Why? |
| Singapore | 2 | 2020 | 3641 | 0.13 | Why? |
| RNA, Viral | 1 | 2021 | 32276 | 0.13 | Why? |
| False Negative Reactions | 1 | 2020 | 1785 | 0.13 | Why? |
| Pyrimidines | 1 | 2021 | 1557 | 0.13 | Why? |
| China | 4 | 2020 | 50654 | 0.12 | Why? |
| Candidemia | 1 | 2017 | 353 | 0.12 | Why? |
| Fever | 2 | 2021 | 7795 | 0.12 | Why? |
| Ethanol | 1 | 2018 | 533 | 0.12 | Why? |
| Measles | 1 | 2020 | 608 | 0.12 | Why? |
| Methylobacteriaceae | 1 | 2011 | 2 | 0.12 | Why? |
| Indoles | 1 | 2021 | 1243 | 0.12 | Why? |
| Klebsiella Infections | 1 | 2017 | 466 | 0.12 | Why? |
| Antimicrobial Stewardship | 1 | 2021 | 931 | 0.12 | Why? |
| Sulfonamides | 1 | 2021 | 1294 | 0.12 | Why? |
| Bacteria | 2 | 2021 | 1897 | 0.12 | Why? |
| Glucocorticoids | 2 | 2019 | 4431 | 0.12 | Why? |
| Risk Assessment | 5 | 2018 | 25439 | 0.12 | Why? |
| Bronchodilator Agents | 1 | 2017 | 444 | 0.12 | Why? |
| Endocarditis | 1 | 2017 | 368 | 0.12 | Why? |
| Protective Factors | 1 | 2018 | 1720 | 0.11 | Why? |
| Age Distribution | 2 | 2018 | 3567 | 0.11 | Why? |
| Myocardial Ischemia | 1 | 2018 | 781 | 0.11 | Why? |
| Drug Combinations | 1 | 2021 | 3852 | 0.11 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.11 | Why? |
| Acute Kidney Injury | 2 | 2018 | 5762 | 0.11 | Why? |
| Overweight | 1 | 2017 | 916 | 0.11 | Why? |
| Citrobacter | 1 | 2010 | 5 | 0.11 | Why? |
| Communicable Disease Control | 1 | 2020 | 29620 | 0.11 | Why? |
| Pyrazoles | 1 | 2021 | 1791 | 0.11 | Why? |
| Headache | 1 | 2021 | 2257 | 0.10 | Why? |
| HIV | 1 | 2017 | 1116 | 0.10 | Why? |
| DNA, Ribosomal | 2 | 2010 | 112 | 0.10 | Why? |
| Neoplasms | 2 | 2018 | 17251 | 0.10 | Why? |
| Bronchi | 1 | 2017 | 1048 | 0.10 | Why? |
| Fatigue | 1 | 2021 | 2479 | 0.10 | Why? |
| Nasopharyngeal Neoplasms | 1 | 2010 | 64 | 0.10 | Why? |
| New York | 1 | 2017 | 2488 | 0.10 | Why? |
| Reagent Kits, Diagnostic | 1 | 2020 | 2149 | 0.10 | Why? |
| Decontamination | 1 | 2019 | 1196 | 0.10 | Why? |
| Suicide, Attempted | 1 | 2016 | 599 | 0.10 | Why? |
| Immunization | 1 | 2019 | 2019 | 0.10 | Why? |
| Swine | 1 | 2018 | 3352 | 0.10 | Why? |
| Kaplan-Meier Estimate | 1 | 2019 | 4260 | 0.10 | Why? |
| Exanthema | 1 | 2019 | 1097 | 0.09 | Why? |
| Severity of Illness Index | 5 | 2020 | 48226 | 0.09 | Why? |
| Meningitis, Bacterial | 1 | 2010 | 111 | 0.09 | Why? |
| Hospitals, Teaching | 1 | 2017 | 1609 | 0.09 | Why? |
| Dengue | 1 | 2021 | 1565 | 0.09 | Why? |
| Prospective Studies | 5 | 2020 | 43301 | 0.09 | Why? |
| Hand Disinfection | 1 | 2018 | 1671 | 0.09 | Why? |
| Antipsychotic Agents | 1 | 2017 | 887 | 0.09 | Why? |
| Hepatitis B | 1 | 2016 | 888 | 0.09 | Why? |
| Tomography, X-Ray Computed | 5 | 2018 | 25144 | 0.09 | Why? |
| Methylprednisolone | 1 | 2019 | 2107 | 0.09 | Why? |
| Heart Defects, Congenital | 1 | 2017 | 933 | 0.09 | Why? |
| Antibodies, Viral | 1 | 2020 | 51949 | 0.09 | Why? |
| ROC Curve | 3 | 2019 | 6024 | 0.08 | Why? |
| Cause of Death | 2 | 2018 | 4823 | 0.08 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2017 | 1454 | 0.08 | Why? |
| Glasgow Coma Scale | 2 | 2017 | 249 | 0.08 | Why? |
| Republic of Korea | 1 | 2020 | 5858 | 0.08 | Why? |
| Critical Care | 4 | 2019 | 14081 | 0.08 | Why? |
| Hospital Mortality | 7 | 2018 | 22087 | 0.08 | Why? |
| World Health Organization | 1 | 2020 | 4213 | 0.08 | Why? |
| Lopinavir | 1 | 2021 | 4308 | 0.08 | Why? |
| Gram-Negative Bacterial Infections | 1 | 2011 | 398 | 0.08 | Why? |
| Health Resources | 1 | 2020 | 2592 | 0.08 | Why? |
| DNA, Fungal | 1 | 2006 | 95 | 0.08 | Why? |
| Accidental Falls | 1 | 2011 | 448 | 0.08 | Why? |
| Ritonavir | 1 | 2021 | 4212 | 0.08 | Why? |
| Scleroderma, Systemic | 1 | 2013 | 583 | 0.08 | Why? |
| Length of Stay | 3 | 2019 | 11042 | 0.08 | Why? |
| Oxygen Inhalation Therapy | 1 | 2019 | 3629 | 0.08 | Why? |
| Sleep Initiation and Maintenance Disorders | 1 | 2017 | 1692 | 0.07 | Why? |
| Health Personnel | 3 | 2020 | 29646 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Wounds and Injuries | 1 | 2017 | 1708 | 0.07 | Why? |
| Seroepidemiologic Studies | 1 | 2020 | 10017 | 0.07 | Why? |
| Disease Progression | 3 | 2018 | 13580 | 0.07 | Why? |
| Acute Disease | 1 | 2017 | 6029 | 0.07 | Why? |
| Immunologic Factors | 1 | 2020 | 4206 | 0.07 | Why? |
| Survival Rate | 1 | 2018 | 9206 | 0.07 | Why? |
| Gastrointestinal Diseases | 1 | 2018 | 2580 | 0.06 | Why? |
| Transplantation, Homologous | 1 | 2006 | 757 | 0.06 | Why? |
| Bone Marrow Transplantation | 1 | 2006 | 343 | 0.06 | Why? |
| Logistic Models | 4 | 2017 | 9089 | 0.06 | Why? |
| India | 1 | 2020 | 11875 | 0.06 | Why? |
| Odds Ratio | 3 | 2019 | 5861 | 0.06 | Why? |
| Age Factors | 3 | 2017 | 21039 | 0.06 | Why? |
| Radiography, Thoracic | 2 | 2011 | 5486 | 0.06 | Why? |
| Cytokines | 2 | 2020 | 15010 | 0.06 | Why? |
| Adolescent | 4 | 2020 | 86841 | 0.06 | Why? |
| Renal Dialysis | 1 | 2018 | 4358 | 0.06 | Why? |
| Fatal Outcome | 2 | 2010 | 3438 | 0.05 | Why? |
| Anti-Inflammatory Agents | 1 | 2020 | 6153 | 0.05 | Why? |
| Treatment Failure | 2 | 2017 | 2106 | 0.05 | Why? |
| Sequence Analysis, DNA | 2 | 2010 | 2830 | 0.05 | Why? |
| Immunosuppressive Agents | 1 | 2019 | 6331 | 0.05 | Why? |
| Population Surveillance | 1 | 2017 | 4967 | 0.05 | Why? |
| Animals | 2 | 2021 | 78931 | 0.05 | Why? |
| Pleural Effusion | 1 | 2006 | 680 | 0.05 | Why? |
| Nervous System Diseases | 1 | 2018 | 4092 | 0.05 | Why? |
| Glutathione S-Transferase pi | 1 | 2018 | 10 | 0.05 | Why? |
| Sensitivity and Specificity | 1 | 2020 | 22971 | 0.05 | Why? |
| Hemochromatosis Protein | 1 | 2018 | 21 | 0.05 | Why? |
| Pregnancy | 1 | 2021 | 23879 | 0.05 | Why? |
| Asthma | 1 | 2017 | 4383 | 0.05 | Why? |
| RNA, Ribosomal, 28S | 1 | 2017 | 13 | 0.05 | Why? |
| Glutathione Transferase | 1 | 2018 | 86 | 0.05 | Why? |
| Case-Control Studies | 4 | 2017 | 17671 | 0.05 | Why? |
| Isoenzymes | 1 | 2018 | 127 | 0.04 | Why? |
| Leukocidins | 1 | 2018 | 47 | 0.04 | Why? |
| Practice Guidelines as Topic | 2 | 2020 | 15421 | 0.04 | Why? |
| Mycological Typing Techniques | 1 | 2017 | 38 | 0.04 | Why? |
| Azathioprine | 1 | 2019 | 161 | 0.04 | Why? |
| Exotoxins | 1 | 2018 | 54 | 0.04 | Why? |
| Biomarkers | 2 | 2018 | 23361 | 0.04 | Why? |
| Candida glabrata | 1 | 2017 | 50 | 0.04 | Why? |
| Fasciotomy | 1 | 2016 | 23 | 0.04 | Why? |
| Hepatitis A Virus Cellular Receptor 1 | 1 | 2018 | 86 | 0.04 | Why? |
| Cyclooxygenase 2 Inhibitors | 1 | 2017 | 48 | 0.04 | Why? |
| Disease Outbreaks | 2 | 2020 | 27595 | 0.04 | Why? |
| Lipocalin-2 | 1 | 2018 | 156 | 0.04 | Why? |
| Restraint, Physical | 1 | 2017 | 74 | 0.04 | Why? |
| GPI-Linked Proteins | 1 | 2018 | 317 | 0.04 | Why? |
| Injury Severity Score | 1 | 2017 | 287 | 0.04 | Why? |
| Thoracic Injuries | 1 | 2017 | 63 | 0.04 | Why? |
| Heart Failure | 1 | 2018 | 6638 | 0.04 | Why? |
| Fluconazole | 1 | 2017 | 145 | 0.04 | Why? |
| Contraindications, Drug | 1 | 2017 | 281 | 0.04 | Why? |
| Poisson Distribution | 1 | 2017 | 348 | 0.04 | Why? |
| Obesity | 1 | 2017 | 7388 | 0.04 | Why? |
| Child | 4 | 2019 | 70012 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
| beta-Lactam Resistance | 1 | 2017 | 150 | 0.04 | Why? |
| Pemphigus | 1 | 2019 | 163 | 0.04 | Why? |
| Diagnosis, Differential | 1 | 2011 | 7220 | 0.04 | Why? |
| Severe Acute Respiratory Syndrome | 1 | 2020 | 12361 | 0.04 | Why? |
| Multivariate Analysis | 2 | 2017 | 5440 | 0.04 | Why? |
| Debridement | 1 | 2016 | 172 | 0.04 | Why? |
| Azoles | 1 | 2017 | 185 | 0.04 | Why? |
| Prednisolone | 1 | 2019 | 443 | 0.04 | Why? |
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2018 | 214 | 0.04 | Why? |
| Italy | 1 | 2020 | 38444 | 0.04 | Why? |
| Young Adult | 4 | 2020 | 93724 | 0.04 | Why? |
| Critical Illness | 1 | 2019 | 17281 | 0.04 | Why? |
| Chi-Square Distribution | 1 | 2018 | 961 | 0.04 | Why? |
| Analysis of Variance | 1 | 2018 | 950 | 0.03 | Why? |
| Statistics, Nonparametric | 1 | 2018 | 1008 | 0.03 | Why? |
| Public Health | 1 | 2020 | 16359 | 0.03 | Why? |
| Salvage Therapy | 1 | 2016 | 417 | 0.03 | Why? |
| Microbial Viability | 1 | 2018 | 406 | 0.03 | Why? |
| Opportunistic Infections | 1 | 2020 | 602 | 0.03 | Why? |
| Infant | 4 | 2019 | 30274 | 0.03 | Why? |
| Rectum | 1 | 2017 | 495 | 0.03 | Why? |
| Dilatation, Pathologic | 1 | 2013 | 78 | 0.03 | Why? |
| Drug Administration Schedule | 1 | 2020 | 2324 | 0.03 | Why? |
| Quarantine | 1 | 2020 | 18418 | 0.03 | Why? |
| Cross-Sectional Studies | 1 | 2020 | 53120 | 0.03 | Why? |
| Enterobacteriaceae | 1 | 2017 | 395 | 0.03 | Why? |
| Chest Pain | 1 | 2017 | 578 | 0.03 | Why? |
| Clinical Laboratory Techniques | 1 | 2020 | 23402 | 0.03 | Why? |
| Pakistan | 1 | 2021 | 2302 | 0.03 | Why? |
| Withholding Treatment | 1 | 2019 | 798 | 0.03 | Why? |
| Social Responsibility | 1 | 2017 | 363 | 0.03 | Why? |
| Cardiovascular Diseases | 1 | 2017 | 11497 | 0.03 | Why? |
| Trachea | 1 | 2017 | 894 | 0.03 | Why? |
| Hypnotics and Sedatives | 1 | 2017 | 624 | 0.03 | Why? |
| Organ Dysfunction Scores | 1 | 2018 | 1475 | 0.03 | Why? |
| Streptococcus pneumoniae | 1 | 2016 | 827 | 0.03 | Why? |
| Esophagus | 1 | 2013 | 139 | 0.03 | Why? |
| Administration, Inhalation | 1 | 2017 | 1647 | 0.03 | Why? |
| Hospitalization | 2 | 2019 | 54280 | 0.03 | Why? |
| Magnetic Resonance Imaging | 1 | 2007 | 6551 | 0.03 | Why? |
| Enoxaparin | 1 | 2017 | 1064 | 0.03 | Why? |
| National Health Programs | 1 | 2017 | 807 | 0.03 | Why? |
| Sex Factors | 2 | 2017 | 11014 | 0.03 | Why? |
| Nasal Mucosa | 1 | 2017 | 1218 | 0.02 | Why? |
| Shock, Septic | 1 | 2019 | 1313 | 0.02 | Why? |
| Emergency Medicine | 1 | 2019 | 936 | 0.02 | Why? |
| Health Care Costs | 1 | 2017 | 1007 | 0.02 | Why? |
| Bronchoscopy | 1 | 2017 | 991 | 0.02 | Why? |
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 1261 | 0.02 | Why? |
| Bacterial Typing Techniques | 1 | 2010 | 273 | 0.02 | Why? |
| Health Facilities | 1 | 2017 | 1230 | 0.02 | Why? |
| Lung | 1 | 2017 | 31049 | 0.02 | Why? |
| Heparin, Low-Molecular-Weight | 1 | 2017 | 1731 | 0.02 | Why? |
| Child, Preschool | 3 | 2019 | 36283 | 0.02 | Why? |
| Multiple Organ Failure | 1 | 2017 | 1724 | 0.02 | Why? |
| Infant, Newborn | 2 | 2019 | 23105 | 0.02 | Why? |
| Diabetes Complications | 1 | 2019 | 2358 | 0.02 | Why? |
| Phenotype | 1 | 2017 | 4037 | 0.02 | Why? |
| Genotype | 1 | 2018 | 4697 | 0.02 | Why? |
| DNA, Bacterial | 1 | 2010 | 835 | 0.02 | Why? |
| Carrier State | 1 | 2017 | 2100 | 0.02 | Why? |
| Cardiac Surgical Procedures | 1 | 2018 | 1931 | 0.02 | Why? |
| Molecular Sequence Data | 1 | 2010 | 3198 | 0.02 | Why? |
| Dyspnea | 1 | 2017 | 3847 | 0.02 | Why? |
| Clinical Decision-Making | 1 | 2017 | 3755 | 0.02 | Why? |
| Patient Care Team | 1 | 2017 | 3556 | 0.02 | Why? |
| Algorithms | 1 | 2019 | 7346 | 0.01 | Why? |
| Lung Diseases, Interstitial | 1 | 2013 | 1476 | 0.01 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.01 | Why? |
| Aging | 1 | 2017 | 3581 | 0.01 | Why? |
| Communication | 1 | 2017 | 5206 | 0.01 | Why? |
| Follow-Up Studies | 1 | 2017 | 17020 | 0.01 | Why? |
| Models, Theoretical | 1 | 2017 | 6659 | 0.01 | Why? |
| Anticoagulants | 1 | 2017 | 9563 | 0.01 | Why? |